Presentation Transcript

1. BioGaia is a healthcare probiotic company Vision: BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products. Business concept: BioGaia´s concept is to develop, market and sell well documented probiotic products worldwide in the form of innovative and appealing dietary supplements and food products. Probiotics:Live microorganisms which when administered in adequate amounts confer a documented health benefit.
2. BioGaia Founded in 1990 Probiotics (Lactobacillus reuteri) 69 employees (Stockholm 23, Lund, 23, Eslöv 13 Raleigh 2, Hiroshima 6, Shanghai 2) Listed on the OMX Nordic Exchange in Stockholm 1998 Products in 50 markets through distributors Contract manufacturing Twopac (50% owned) Holds 229 patents in 23 families
3. Change of focus Dietary Supplements Infant formula Functional Foods / Dairies Animal Health 1990 1995 2000 2005 2010
4. Business model – three networks
5. Distribution partner network
6. BioGaia Brand Branding for Health professionals Sold in over 40 countries 43 % of sales of finished products (incl. co branding 52%) Build value, less dependence on distributors and patents
7. Competition Strategy Clinical trials of high quality Attractive and unique formulations and delivery systems. Strong partner support
8. Scientific network
9. Clinical trials supporting the use of BioGaia Probiotics with L. reuteri – including the strains L. reuteriProtectis, Prodentis and Gastrus Completed clinical trialsFeb. 2012 92studies in over 7,700individuals, whereof: 63randomised, double-blind / blind, placebo-controlled studies in 6,169 subjects 29open studies in1,518 subjects 30 studies in 0-3y in 3,589 subjects Results are published in55scientific articles and 3 doctoral theses.
10. * Number of published clinical studies by April 2012 Product Indications Overview L. reuteriDSM 17938 (ATCC 55730) BioGaia ProTectis (74*) Gut Motility Diarrhoea Neonatal Intensive Care Regurgitation NecrotisingEnterocolitis Prevention Gingivitis/plaque Infantile colic Acute Gastroenteritis Periodontitis Antibiotic AssociatedDiarrhoea (AAD) Constipation Feeding tolerance Functional abdominal Pain (FAP) BioGaia ProDentis (9*) L. reuteriDSM 17938 & L. reuteriATCC PTA 5289 L. reuteriDSM 17938 & L. reuteriATCC PTA 6485 BioGaia Gastrus Gum Integrity Stomach Health H. Pylori infection/inflammation H. pylori side effects
11. Health protection by L. reuteri in children Children (4-10m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)
12. Health economics of L. reuteri supplementation Children (4-10m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)
13. L. reuteri preventing antibiotic-associated diarrhoea P=0.02 Adults in hospital on antibiotics Supplemented with L. reuteri or placebo for 4 weeks Cimperman et al. ASPEN meeting February 2009
14. L. reuterieliminates infantile colic ** *** Crying time (median; mins/day) *** *** Savino et al. Pediatr Res 58: 411 (2005) Savino et al. Pediatr, in press (2006) ** *** P < 0.01 P < 0.001 Days of supplementation
15. Attractive and unique formulations and delivery systems
16. Strong partner support Clinical trials Marketing and PR support BioGaia Academy Web site Participation in conferences Speakers at symposiums Education of sales representatives
17. BioGaia current products ProTectis Digestive Health ProDentis OralHealth Gastrus Stomach Health ProTectis Baby ProTectis D3 Baby ProTectis Junior ProTectis Baby/Junior ProTectis ProDentis ProDentis Gastrus Drops Lozenges Tablets Tablets ORS Tablets Drops Drops
18. Competitors Valio (Finland) InstitutRosellLallemand (France) Merck (Germany) Novartis Probi (Sweden) Danone Chr Hansen/Danisco SanofiAventis Ferrosan (Pfizer) P&G Local competitors
19. Drops launched: 50 countries Armenia Austria Azerbajdzjan Belarus Belgium Bolivia Bulgaria Canada Chile Czech Republic Croatia Denmark Dominican Republic Estonia Finland France Georgia Germany Greece Guatemala Hungary Ireland Israel Italy Japan Jordan Kazakhstan Latvia Lebanon Lithuania Luxemburg Malaysia Mexico Peru Poland Portugal Romania Russia Saudi Arabia Serbia Singapore Slovakia Slovenia South Africa South Korea Spain Sweden Turkey Ukraine USA Black: BioGaia brand Blue: Co branding Red: Distributor’s brand
20. Drops signed but not launched: 27 countries Paraguay Puerto Rico Qatar Syria Taiwan Turkmenistan UAE Uzbekistan Venezuela Yemen Australia Bahrain Brazil China Colombia Costa Rica Cyprus Ecuador Indonesia Iran Kirgizistan Kuwait Moldavia Morocco New Zealand Oman Panama Black: BioGaia brand
21. Tablets launched: 47 countries Australia Belgium Bolivia Botswana Brazil Bulgaria Canada Chile Czech Republic Croatia Denmark Dominican Republic Estonia Finland France Greece Guatemala Georgia Hong Kong Indonesia Italy Japan Jordan Kazakhstan Lebanon Luxemburg Malaysia Mexico Namibia New Zealand Peru Poland Portugal Romania Russia Serbia Singapore Slovakia Slovenia South Africa South Korea Spain Swaziland Sweden Turkey Ukraine USA Black: BioGaia Brand Blue: Co branding Red: Distributor’s brand
22. Tablets signed but not launched: 27 countries Puerto Rico Qatar Syria Taiwan Turkmenistan UAE Uzbekistan Venezuela Yemen Kuwait Latvia Lithuania Moldavia Morocco Oman Panama Paraguay Philippines Armenia Azerbajdzjan Bahrain Belarus Colombia Costa Rica Ecuador Iran Kirgiztan Black: BioGaia brand
23. BioGaia Oral Rehydration Solution (ORS) Launched Plannedlaunch
24. BioGaiaOral Health Products Launched Plannedlaunch
25. Key events second quarter 2012 Agreement with Gerber for sales of drops and ORS in United States Study in Type 2 Diabetes Agreement for oral health products in Czech Republic, the Benelux countries and South Africa Agreement for tablets and drops in Taiwan
26. Key events first quarter 2012 BioGaia extends collaboration with Nestlé New study: Lactobacillus reuteriProtectis reduced diarrhoea in children Launches of Strawberry tablets in U.SA, drops and tablets in Bolivia, ORS in Greece and infant formula in 6 countries
27. Nestlé Agreement Sale of licence for EUR 50.8 (EUR 40 million, paid and accounted for in q1 2012) Further projects will be announced closer to launch (Gerber – June, 2012) Revenue from Nestlé is estimated in 2012 (excluding the up-front payment) to 50% of sales during 2011, in 2013 close to 2011 level and from 2014 and forward more than 2011.
28. Sales development 2007-2011 (SEK Million) +36%
29. EBIT and profit Profit Margin: 35% Ebit Margin 33% 103,2 Financial target: at least 30% EBIT margin EBIT margin = EBIT/Sales Profit margin = Profit before tax/Sales
30. Income statement first half-year, 2012vs first half-year, 2011
31. Income statement June 2012 / June 2011 (rolling 12 months)
32. Balance sheet 30 June 2012 (MSEK)
33. Cash flow statement first half-year 2012 (MSEK)
34. Sales per segment (MSEK) (Licenserevenueexcluded)
35. Sales per segment q1 2009- q2 2012 (rolling 12 months) (MSEK) (License revenue excluded)
36. Quarterly development q1 2009- q2 2012 (rolling 12 months) (MSEK) (Licenserevenueexcluded)
37. Sales per geographical market(MSEK)
38. The Board Jörgen Thorball Inger Holmström David Dangoor Chairman Paula Zeilon Jan Annwall Stefan Elving Thomas Flinck
39. Major Shareholders 30 June, 2012 Total number of shareholders 30 June 2012: 7,453 Foreign owners: 38% of capital (28% of votes)
40. Present focus Continued focus on BRIC-countries Change of distributors in a number of countries Ongoing trials for several new indications New delivery systems under development A number of development projects with Nestlé